Who Generates Higher Gross Profit? GSK plc or Ascendis Pharma A/S

GSK vs. Ascendis: A Decade of Gross Profit Comparison

__timestamp	Ascendis Pharma A/S	GSK plc
Wednesday, January 1, 2014	13983000	15683000000
Thursday, January 1, 2015	8118000	15070000000
Friday, January 1, 2016	4606000	18599000000
Sunday, January 1, 2017	1530000	19844000000
Monday, January 1, 2018	10581000	20580000000
Tuesday, January 1, 2019	13375000	21891000000
Wednesday, January 1, 2020	6953000	22395000000
Friday, January 1, 2021	4255000	22511000000
Saturday, January 1, 2022	39037000	19770000000
Sunday, January 1, 2023	222323000	21763000000
Monday, January 1, 2024	319383000

Infusing magic into the data realm

A Tale of Two Companies: GSK plc vs. Ascendis Pharma A/S

In the competitive world of pharmaceuticals, gross profit is a key indicator of a company's financial health. Over the past decade, GSK plc has consistently outperformed Ascendis Pharma A/S in terms of gross profit. From 2014 to 2023, GSK's gross profit has remained robust, peaking at approximately $22 billion in 2021. In contrast, Ascendis Pharma A/S, a relatively newer player, has shown significant growth, with its gross profit surging by over 1,500% from 2014 to 2023, reaching around $222 million. This remarkable growth trajectory highlights Ascendis Pharma's potential in the industry, despite its current smaller scale compared to GSK. As the pharmaceutical landscape evolves, it will be intriguing to see how these two companies continue to navigate their financial journeys.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025